Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ibrutinib in preparation of drugs for treating chronic hypoxic pulmonary hypertension

A technology of pulmonary arterial hypertension and ibrutinib, applied in drug combinations, pharmaceutical formulas, organic active ingredients, etc., can solve the problems of irreversible pulmonary hypertension process, uncertain effect of targeted drug therapy, etc., and achieve the effect of drug safety

Inactive Publication Date: 2019-11-05
HUAZHONG UNIV OF SCI & TECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In order to solve the problems in the prior art, the present invention provides a use of ibrutinib in the preparation of drugs for the treatment of chronic hypoxic pulmonary hypertension, which overcomes the current symptomatic support in the treatment of chronic hypoxic pulmonary hypertension in the prior art The treatment plan cannot reverse the progression of pulmonary arterial hypertension and the effect of targeted drug therapy is uncertain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ibrutinib in preparation of drugs for treating chronic hypoxic pulmonary hypertension
  • Application of ibrutinib in preparation of drugs for treating chronic hypoxic pulmonary hypertension
  • Application of ibrutinib in preparation of drugs for treating chronic hypoxic pulmonary hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Ibrutinib is added with pharmaceutically acceptable excipients and prepared into various dosage forms according to conventional methods, such as various specifications of liquid injections, powder injections, emulsions for injection, tablets, pills, capsules, ointments, creams, patches , Liniments, powders, sprays, implants, drops, suppositories, ointments, confectionery, etc.

[0020] The route of administration of Ibrutinib includes various routes of administration: oral administration, injection administration, implant administration, intracavity administration, sublingual administration, anal administration, transdermal administration, internal and external application, etc. .

experiment example 1

[0022] In order to prove the technical means, purpose and experimental effect of the experimental invention, the following will further illustrate the present invention with specific experimental examples.

[0023] (1) Experimental materials

[0024] 1. Laboratory animals

[0025] SD rat, male, 350±10g, purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd. The experimental animals were placed in the modeling area for 7 days after they were purchased.

[0026] Animal feeding conditions: constant temperature 25±1℃, constant humidity 55±5%, keep light and dark for 12 hours each, feed and water normally.

[0027] 2. Experimental drugs and configuration methods:

[0028] Ibrutinib (ibrutinib), purchased from Selleck, storage conditions: 4°C, protected from light. Ibrutinib 22.5 mg was accurately weighed, stirred until it was completely dissolved in 25 μl DMSO, diluted with 2.5 ml of saline, and stored.

[0029] (2) Experimental method

[0030] 1. Model construction and dr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of ibrutinib in preparation of drugs for treating chronic hypoxic pulmonary hypertension. The experimental result shows that rising of right ventricular pressure can be significantly alleviated by using the ibrutinib to treat rats in a hypoxic group, an HE staining result shows that the thickness increasing degree of pulmonary artery medial membranes of the ratsin the hypoxic group treated by the ibrutinib is alleviated, and the number of muscularized arterioles is decreased significantly. The ibrutinib can provide a potential treatment prospect for treatment of the chronic hypoxic pulmonary hypertension.

Description

Technical field [0001] The invention belongs to the technical field of application of ibrutinib, and in particular relates to the use of ibrutinib in preparing a medicine for treating chronic hypoxic pulmonary hypertension. Background technique [0002] Pulmonary hypertension is a chronic and complex cardiopulmonary vascular disease caused by multiple factors. Its main pathological features are increased pulmonary artery pressure, pulmonary resistance vascular proliferation and structural remodeling. Patients with pulmonary hypertension often go to a doctor late. Once diagnosed, such patients often develop right heart failure and even die within a few years. Patients with pulmonary hypertension have a poor prognosis, low long-term survival rate, and high case fatality rate. It has become a public health event endangering human health. [0003] Chronic hypoxic pulmonary hypertension is the third type classified by the European Society of Cardiology. It is the cause of respiratory d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/519A61P9/12
CPCA61K31/519A61P9/12
Inventor 胡清华朱莉萍李彤稂与恒范晓航刘丙勋任荣玲
Owner HUAZHONG UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com